|
| 36460217 | Retinopathy as an independent predictor of all-cause mortality in individuals with type 2 diabetes. | | 2023 |
| 36376644 | Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study. | Diabetes Therapy | 2023 |
| 36111434 | Treatment patterns and glycated haemoglobin levels over 36â¿¿months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study. | Diabetes, Obesity and Metabolism | 2023 |
| 38032850 | Performance of Tandem Control IQ during outdoor physical activity in children and adolescents with type 1 diabetes. | | 2023 |
| 37712257 | ANGPTL3 Deficiency and Risk of Hepatic Steatosis. | | 2023 |
| 37547276 | The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. | | 2023 |
| 36906837 | HbA1c trajectories over 3â¿¿years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study. | Diabetes Obes Metab | 2023 |
| 37084893 | The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care. | | 2023 |
| 36897149 | Risk factor variability and cardiovascular risk among patients with diabetes: a nationwide observational study. | | 2023 |
| 36948942 | Corrigendum to Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins > Nutr Metab Cardiovasc Dis. 2022 Sep;32(9):2255-2263. | | 2023 |
| 37312666 | Sustained increase in physical fitness independently predicts improvements in cardiometabolic risk profile in type 2 diabetes. | | 2023 |
| 37254688 | Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials. | | 2023 |
| 37308927 | Outpatient healthcare costs associated with overweight and obesity in Italy. | | 2023 |
| 35073913 | HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target. | Cardiovascular Diabetology | 2022 |
| 35909534 | Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes. | Frontiers in Endocrinology | 2022 |
| 35594134 | Accuracy of the Standard GlucoNavii Mentor in Blood Glucose Monitoring According to International Organization for Standardization 15197:2013 Criteria. | JMIR Diabetes | 2022 |
| 35527995 | Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. | Front Endocrinol (Lausanne) | 2022 |
| 36167264 | A prediction model to assess the risk of egfr loss in patients with type 2 diabetes and preserved kidney function: The amd annals initiative. | Diabetes Research and Clinical Practice | 2022 |
| 35378795 | Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes. | Medical Devices: Evidence and Research | 2022 |
| 35870573 | Prediction of complications of type 2 Diabetes: A Machine learning approach. | Diabetes Research and Clinical Practice | 2022 |
| 36328211 | Sustained decreases in sedentary time and increases in physical activity are associated with preservation of estimated β-cell function in individuals with type 2 diabetes. | Diabetes Research and Clinical Practice | 2022 |
| 35926587 | Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study. | Indian Heart J | 2022 |
| 35546275 | Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. | Diabetes Obes Metab | 2022 |
| 36400169 | Role of telemedicine during COVID-19 pandemic in type 2 diabetes outpatients: The AMD annals initiative. | Diabetes Research and Clinical Practice | 2022 |
| 36733804 | Obesity management: Attitudes and practice of Italian endocrinologists. | | 2022 |
| 34018307 | Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis. | Diabetes/Metabolism Research and Reviews | 2022 |
| 33624040 | A few clinical features improve the prediction of mortality and cardiovascular outcomes in patients with type 2 diabetes. | European Journal of Preventive Cardiology | 2022 |
| 35033162 | The adolescent with obesity: what perspectives for treatment? | Italian Journal of Pediatrics | 2022 |
| 34728529 | Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2). | Diabetes Care | 2022 |
| 35029066 | Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. | Endocrinol Diabetes Metab | 2022 |
| 34495396 | Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study. | Acta Diabetologica | 2022 |
| 35114299 | Quality of life in people with type 2 diabetes in the 3Â years following initiation of second-line therapy: The DISCOVER study. | Diabetes Res Clin Pract | 2022 |
| 34477563 | Perceived Benefits, Barriers, and Facilitators of a Digital Patient-Reported Outcomes Tool for Routine Diabetes Care: Protocol for a National, Multicenter, Mixed Methods Implementation Study. | JMIR Research Protocols | 2021 |
| 32385580 | Misperceptions and barriers to obesity management: Italian data from the ACTION-IO study. | Eating and Weight Disorders | 2021 |
| 34079308 | Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. | ClinicoEconomics and Outcomes Research | 2021 |
| 33852202 | Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. | Diabetes Obes Metab | 2021 |
| 33852196 | Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. | Diabetes Obes Metab | 2021 |
| 33740123 | Telemedicine and urban diabetes during COVID-19 pandemic in Milano, Italy during lock-down: epidemiological and sociodemographic picture. | Acta Diabetol | 2021 |
| 33890476 | Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. | Journal of the American Heart Association | 2021 |
| 33676499 | Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. | Cardiovascular Diabetology | 2021 |
| 33570253 | Type 2 diabetes and heart failure: insights from the global DISCOVER study. | ESC Heart Fail | 2021 |
| 34154892 | Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. | Nutrition, Metabolism and Cardiovascular Diseases | 2021 |
| 33941550 | Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. | BMJ Open Diabetes Res Care | 2021 |
| 33606897 | Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. | Diabetes, Obesity and Metabolism | 2021 |
| 34252505 | Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. | Diabetes Res Clin Pract | 2021 |
| 33441402 | Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. | BMJ | 2021 |
| 34302913 | Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. | Diabetes Res Clin Pract | 2021 |
| 33351177 | Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study. | Diabetes Therapy | 2021 |
| 33269544 | Impact of Covid-19 epidemic on the activities of a blood centre, transfusion support for infected patients and clinical outcomes. | Transfusion Medicine | 2021 |
| 34686406 | Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. | J Diabetes Complications | 2021 |